Business
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc.
About this update from Neumora Therapeutics, Inc.
[{"type":"text","content":"Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET\nWATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will host a roundtable discussion on the neuropsychiatric treatment landscape and role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The discussion will feature leading experts in neuropsychiatry and will take place on Thursday, September 12 at 8:00 a.m. ET. “We look forward to an engaging discussion with our panel of distinguished medical experts and to providing an overview of the potential for navacaprant to make a difference for patients,” said Henry Gosebruch, chief executive officer, Neumora. “It is clear that there is significant excitement among the scientific community regarding the potential of KORAs across many neuropsychiatric indications. We share their enthusiasm and are pleased to be executing the comprehensive Phase 3 KOASTAL program with navacaprant in MDD in the monotherapy setting and a Phase 2 study in bipolar depression. We believe navacaprant has the potential to reshape the treatment of these serious brain disorders. We look forward to reporting topline data from our first Phase 3 study, KOASTAL-1, in the fourth quarter.” The program agenda will feature the following topics and speakers: Global Brain Disease: Neumora’s Mission and Pipeline Josh Pinto, Ph.D., Chief Financial Officer The Role of Kappa Opioid Receptors in MDD and Overview of Navacaprant Phase 2 Data Bill Aurora, Pharm.D., Chief Strategy Officer Indication Opportunities for Navacaprant: MDD, BPD, and Beyond Rob Lenz, M.D., Ph.D., Head of Research and Development Fireside Chat: A Discussion on the Neuropsychiatric Treatment Landscape and Opportunity for Navacaprant Roger McIntyre, M.D., University of TorontoSanjay Mathew, M.D., Baylor College of MedicineJohn Krystal, M.D., Yale University School of Medicine Company Outlook: A Look Ahead Henry Gosebruch, Chief Executive Officer Webcast InformationThe event will begin at 8:00 a.m. ET on Thursday, September 12, 2024. Participants can register for the live webcast here. In addition, the live webcast of the event will be available on the ...